• Skip to main content
  • Skip to footer

Life Sciences British Columbia

  • Members Area |
  • Contact Us
  • SearchSearch
  • About
    • Board of Directors
    • Management
    • Vision & Mission
    • LSBC Hall of Fame
  • Awards
  • Membership
    • Sponsors
    • Members Directory
    • Members Area
    • Membership Benefits
    • Membership Discounts
    • Members Services
    • Members Map
    • Become a Member
  • Events
    • Calendar
    • Webinars
    • Past Events
      • 2023 Events
      • 2022 Events
      • 2021 Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
  • News
    • All News
    • Member News
    • Industry News
    • LSBC in The News
    • Publications
    • BC Labour Market Study
  • Resources
    • All Resources
    • Grants and Funding
      • Funding Competitions
      • Wage Subsidies
    • Academic Institutions
    • Government
      • Federal
      • Provincial and Municipal
    • Association Partners
    • Programs
    • Volunteering
  • Jobs
    • Job Board
    • Post a Job
    • Career Events
  • Contact Us
  • Login

Boehringer Ingelheim

Member Profile

Since our arrival in Canada in 1972 we have played a varied and integral role in the health of Canadians. We are committed to finding medical breakthroughs and investing in research, development and medicine for therapies which fulfill unmet medical needs.

Through our participation in medical and pharmaceutical research, both in Canada and worldwide, we have contributed to significant improvements in healthcare and developed innovative and costeffective medicines. We have earned a reputation as a leader in the treatment of respiratory diseases, in particular Chronic Obstructive Pulmonary Disease (COPD), and have broadened the scope of our work to include diseases such as hypertension, stroke, arthritis, benign prostatic hyperplasia (BPH), Parkinson's disease and HIV/AIDS.

We are constantly seeking new and better ways to treat people and animals. In the space of just two years, we have introduced several new products and have a number of new compounds in the pipeline. We have participated in joint ventures with other top multinational pharmaceutical companies - ventures that have improved quality of life for many thousands of Canadians and have perhaps saved the lives of thousands more. Our Vetmedica Division is an accomplished leader in veterinary medicine, offering innovative solutions in biologicals and specialty pharmaceuticals for beef and dairy cattle, swine, companion animals and horses.

While our German parent company stands among the world’s 20 largest human pharmaceutical research and development businesses, it has remained a family held company for over a century. As our ownership has remained unchanged, so have our guiding principles. Since our founding, we have practiced excellence, innovation and value in the discovery of medicines and services, and we have always acted in the firm knowledge that people and service are our priorities.

Sector
Biotechnology, Global Pharmaceutical Corporations, Therapeutics
Area of Expertise
  • Cardiovascular Disease
  • Metabolic Diseases
  • Oncology
  • Therapeutics
Company Stage Clinical Stage, Commercial Stage, Public Company

Member Profile

Biotechnology, Global Pharmaceutical Corporations, Therapeutics

Boehringer Ingelheim

Bronze Sponsor

  • Website www.boehringer-ingelheim.ca
  • Address
    5180 South Service Road
    Burlington, ON
    L7L 5H4
    Follow us:
  • Twitter
  • Facebook
  • LinkedIn
  • Instagram
  • News
  • Jobs

March 23, 2023

Health Canada Approves First Treatment Option for Generalized Pustular Psoriasis Flares in Adults

February 23, 2023

Philanthropic Partnership Sets sights on Sustainable Improvements to Health Care

January 25, 2023

University Health Network and Boehringer Ingelheim Canada Partner to Impact Patients Lives and Help a Healthcare System Under Strain

December 7, 2022

Phase III Trial Demonstrated Jardiance® is the First SGLT2 Inhibitor to Show Statistically Significant Reduction in Blood Sugar Levels in Children and Adolescents with Type 2 Diabetes

November 29, 2022

Improving Health Outcomes for Patients Living with Interstitial Lung Disease and Addressing the Gaps in Care is the Aim of a New Collaboration

No current content.

  • Twitter
  • Linkedin
Tweets by Boehringer Ingelheim
Connect with us LinkedIn

© 2023 Life Sciences BC  |  Privacy Policy

  • Current Jobs
  • Event Calendar
  • All News
  • Member Directory
    Connect with us
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
Contact Us